Completed PHASE2 INTERVENTIONAL 5-arm NCT00570336

Study of CTS-1027 in Hepatitis C Patients

A Dose Response Study of CTS-1027 in Hepatitis C Patients

Sponsor: Conatus Pharmaceuticals Inc.

Conditions Chronic Hepatitis C Virus Infection

Updated 8 times since 2017 Last updated: Sep 14, 2010 Started: Dec 31, 2007 Primary completion: Jul 31, 2009 Completion: Jul 31, 2009

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE2 trial investigates Chronic Hepatitis C Virus Infection and is currently completed. Conatus Pharmaceuticals Inc. leads this study, which shows 8 recorded versions since 2007 — indicating limited longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

Change History

8 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE2
Sep 2024 — Sep 2025 [monthly]

Completed PHASE2
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2
Apr 2022 — Jul 2024 [monthly]

Completed PHASE2
Jan 2021 — Apr 2022 [monthly]

Completed PHASE2

▶ Show 3 earlier versions

Jun 2018 — Jan 2021 [monthly]

Completed PHASE2
Feb 2017 — Jun 2018 [monthly]

Completed PHASE2
Jan 2017 — Feb 2017 [monthly]

Completed PHASE2

First recorded

Dec 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Conatus Pharmaceuticals Inc.
FGK Clinical Research GmbH

Data source: Conatus Pharmaceuticals Inc.

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Atlanta, United States , Aurora, United States , Birmingham, United States , Boston, United States , Cincinnati, United States , Cleveland, United States , Durham, United States , Houston, United States , La Jolla, United States , Miami, United States and 8 more locations